Clinical Trials Browser

monalizumab × Thoracic × Clear all

NCT05903092 2026-04-07

MOZART

Phase 2 Suspended

Small Cell Lung Carcinoma

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05221840 2026-01-27

PACIFIC-9

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07146230 2025-12-24

SPRINT 2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1 Completed

26 enrolled 17 charts

Lung Neoplasms

NCT03822351 2024-10-08

COAST

Phase 2 Completed

189 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms